Results 201 to 210 of about 484,964 (356)

Less Symptom Improvement in Patients Undergoing TAVI With Concomitant COPD, Atrial Fibrillation and Heart Failure

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Comorbidities like a history of chronic obstructive pulmonary disease (COPD), atrial fibrillation (AF) and heart failure (HF) can cause similar symptoms as aortic stenosis (AS). However, how they influence symptom improvement and long‐term outcomes after transcatheter aortic valve implantation (TAVI) is unclear.
Kees H. van Bergeijk, Constantijn S. Venema, Bob Ophuis, Luca H. Plekkenpol, Mara Tomei, Hayman Al‐Barwary, Jasper Tromp, Yoran M. Hummel, Wouter Ouwerkerk, Ad F. M. van den Heuvel, Hindrik W. van der Werf, Yvonne L. Douglas, Jonas Lanz, Stefan Stortecky, Daijiro Tomii, Thomas Pilgrim, Stephan Windecker, Edoardo Pancaldi, Matteo Pagnesi, Marianna Adamo, Adriaan A. Voors, Joanna J. Wykrzykowska   +21 more
wiley   +1 more source

Artificially Induced Resistance of Trichophyton Gyseum to Pelargonic Acid**From the Section of Dermatology, Department of Medicine, University of Chicago.

, 1949
John C. Murphy, Stephen Rothman
openalex   +1 more source

Allyship in dermatology

International Journal of Women's Dermatology, 2021
Brittany Feaster, Amy J. McMichael
openaire   +4 more sources

Tislelizumab: Structural Innovations and Expanding Clinical Horizons in Next‐Generation PD‐1 Immunotherapy

Chronic Diseases and Translational Medicine, EarlyView.
The interaction of tislelizumab with PD‐1/PD‐L1 in the tumor microenvironment. Tislelizumab targets PD‐1 on T cells, blocking its interaction with PD‐L1 on tumor cells. This action is facilitated by a modified F(ab) region that limits Fc‐γ receptor binding, thereby enhancing the antitumor immune response. ABSTRACT Tislelizumab is a next‐generation PD‐1
Thy T. Nguyen, Bohan Zhang, Luke Zhong, Xiuyi Liang, Letao Bo   +4 more
wiley   +1 more source

Dermatology [PDF]

Postgraduate Medical Journal, 1990
openaire   +3 more sources

Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial. [PDF]

Ann Dermatol
Lee S, Kim JE, Lew BL, Huh CH, Kim J, Kwon O, Kim MB, Lee YW, Lee Y, Park J, Kim S, Kim DY, Choi GS, Kang H.   +13 more
europepmc   +1 more source

Pharmacokinetics and Bioequivalence of a Novel Extended‐Release Formulation of Methylphenidate Hydrochloride for Attention‐Deficit/Hyperactivity Disorder

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Extended‐release (ER) formulations of the stimulant methylphenidate are commonly used to treat attention‐deficit/hyperactivity disorder in both children and adults. Previous studies have shown that the clinical effectiveness of long‐acting methylphenidate formulations is closely tied to the drug's pharmacokinetic (PK) profile, highlighting the
Ann C. Childress, Ahmad AL‐Sabbagh, Jeffrey H. Newcorn   +2 more
wiley   +1 more source

Meyerson's Phenomenon Induced by Molluscum Contagiosum in an Adult: A Rare Case Report. [PDF]

Clin Cosmet Investig Dermatol
Wu D, Xu J, Wu L.
europepmc   +1 more source

Redefining the Skin Barrier: A Microbiome‐Integrated Multilayered Defense Model

Barrier Immunity, EarlyView.
ABSTRACT The skin constitutes a dynamic interface orchestrating a sophisticated multilayered defense system comprising physical, chemical, immune, and microbial barriers. This review synthesizes current understanding of the structural and functional integration of these barriers, emphasizing their synergistic interactions in maintaining cutaneous ...
Jingjing Xia, Mathias Hochgerner, Qingzhen Wei, Xian'ge Zhong, Jiucun Wang   +4 more
wiley   +1 more source

Consensus-Based Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): Basic Therapy, Topical Therapy, and Conventional Systemic Therapy. [PDF]

Ann Dermatol
Ko HC, Woo YR, Ko JY, Kim HO, Na CH, Bae Y, Seo YJ, Shin MK, Ahn J, Lew BL, Lee DH, Lee SE, Lee SH, Lee YW, Lee JH, Jang YH, Jeon J, Choi SY, Han JH, Han TY, Son SW, Cho SH.   +21 more
europepmc   +1 more source